Nanoimmunoassay onto a screen printed electrode for HER2 breast cancer biomarker determination.

TitleNanoimmunoassay onto a screen printed electrode for HER2 breast cancer biomarker determination.
Publication TypeJournal Article
Year of Publication2014
AuthorsPatris, S., P. De Pauw, M. Vandeput, J. Huet, P. Van Antwerpen, S. Muyldermans, and J-M. Kauffmann
Date Published2014 Dec

A chip format sandwich-type immunoassay based on Nanobodies(®) (Nbs) with the Human Epidermal Growth Factor Receptor (HER2) extracellular domain as antigen model has been developed. The HER2 is considered as an important biomarker because its overexpression causes an aggressive type of breast cancer. Nbs are single domain antigen-binding fragments derived from camelid heavy-chain antibodies. The strategy of the presently developed sandwich immunoassay takes advantage of the small size of Nbs for the detection of the electroactive redox tracer onto the screen printed electrode (SPE). A capture anti HER2 Nb was covalently immobilized onto the SPE, and the detection Nb, raised against another epitope of HER2, was labeled with horseradish peroxidase (HRP). The biosensor signal corresponded to the electroreduction of para-quinone generated at the SPE by the HRP in the presence of hydroquinone and hydrogen peroxide. The best performing and optimized immunoassay conditions consisted of 2 and 20 min for the first and the second incubation times, respectively. The amperometric signal obtained was proportional to the logarithm of HER2 concentration between 1 and 200 µg/mL and the modified SPE storage stability lasted for at least three weeks. Determination of HER2 in human cells has been realized.

Alternate JournalTalanta
PubMed ID25159394
Research group: